Anti-anxiety activity of Eucalyptus tereticornis n-hexane extract in Wistar albino rats

Authors

  • Shyamjith Manikkoth Department of Pharmacology, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India
  • Sheeba Damodar Department of Pharmacology, Academy of Medical Sciences, Pariyaram, Kannur, Kerala, India
  • Melinda Sequeira Department of Pharmacology, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India
  • Kevin Samuel M.B.B.S Intern, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20170816

Keywords:

Anti-anxiety, Eucalyptus terteticornis, Hexane extract, Wistar rats

Abstract

Background: To find out a new agent with a high therapeutic index for the treatment of anxiety, an indigenous medicinal plant Eucalyptus terteticornis was screened for its effect on anxiety in experimental animal model.

Methods: Thirty six adult Wistar albino rats of both sexes weighing 175-200g were divided into three groups: Group I: DMSO 10% (0.1ml/200g), Group II: hexane extract of leaves of Eucalyptus terteticornis (ETHE) (100mg/kg/body weight), Group III: Diazepam (1mg/kg orally). All test compounds were administered orally for ten days. On tenth day, after one hour of test compounds administration, Wistar rats were taken for elevated plus maze (EPM) and light dark arena (LDA) tests. Statistical comparisons among the groups were performed by One-way analysis of variance (ANOVA) followed by Tukey Krammer test.

Results: The results showed that ETHE treated animals (Group II) significantly (p <0.001) increased the time spent in open arms of EPM and in bright arena of LDA on comparing with normal (Group I).

Conclusions: The anti-anxiety activity of Eucalyptus terteticornis can be due to its effect on brain neurotransmitters or due to antioxidant property.

References

Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE. What is an anxiety disorder? Depression and anxiety. 2009;26(12):1066-85.

Nesse RM. Fear and fitness: An evolutionary analysis of anxiety disorders. Ethology and sociobiology. 1994;15(5):247-61.

Aswini A, Tarun K, Ajay M, Anil H. Anxiety disorders: A review. International Research Journal of Pharmacy. 2011;2(5):18-23.

Pollack MH. Unmet needs in the treatment of anxiety disorders. Psychopharmacology bulletin. 2003;38(1):31-7.

Manikkoth S, Chandrashekar R, Rao SN. Anti-anxiety effect of ethanolic extract of leaves of Tylophora indica in Wistar albino rats. International Journal of Research in Ayurveda and Pharmacy. 2013;4(1):127-9.

Kaplan H, Sadock B. Synopsis of psychiatry. 8th. Edition. Williams & Wilkins. Baltimor, 1998.

Kessler RC, Avenevoli S, Costello J, Green JG, Gruber MJ, McLaughlin KA, et al. Severity of 12-month DSM-IV disorders in the national comorbidity survey replication adolescent supplement. Archives of general psychiatry. 2012;69(4):381-9.

Tripathi KD. Essentials of medical pharmacology. JP Medical Ltd; 2013.

Badrunnisa S, Ramanath Pai V, Shantaram M. Antibacterial activity of Eucalyptus tereticornis extracts for in use coolants of steel industry. J of Res in Pha and Bio Sci. 2011;2(4):1789-94.

Jain P, Nimbrana S, Kalia G. Antibacterial activity and phytochemical analysis of Eucalyptus tereticonis bark and leaf methanolic extracts. Int J Pharm Sci Rev Res. 2010;4(1):126-8.

Shahraki A, Shahraki M. The comparison of Eucalyptus aqueous extract and insulin on blood sugar, and liver enzymes in diabetic male rats. Zahedan Journal of Research in Medical Sciences. 2013;15(6):25-8.

Holmes A, Murphy DL, Crawley JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biological psychiatry. 2003;54(10):953-9.

Gupta SK. Drug screening methods. Jaypee Brothers; 2004.

Pamar NS, Shiv P. Evaluation of drugs acting on central nervous system in screening methods in pharmacology.1st edition. New Delhi, Narosa publishing house pvt ltd; 2006:173-146.

Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. 2nd edition. New York: Guilford Press; 2002.

Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Archives of Internal Medicine. 2006;166(19):2109-16.

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general psychiatry. 2005;62(6):593-602.

Rauniar GP, Deo S, Bhattacharya SK. Evaluation of anxiolytic activity of tensarin in mice. Kathmandu University Medical Journal. 2007;5(8):188-94.

Verma H, Agrawal N, Shri R, Kumar S, Patra A. Anxiolytic effect of Ocimum gratissimum on the elevated plus maze model of anxiety in mice. Pharmacologyonline. 2008;3:244-9.

Jaiswal AK, Battacharya SK. Effects of Shilajit on memory, anxiety and brain monoamines in rats. J Indian of Pha. 1992;24:12-7.

Downloads

Published

2017-02-24

How to Cite

Manikkoth, S., Damodar, S., Sequeira, M., & Samuel, K. (2017). Anti-anxiety activity of Eucalyptus tereticornis n-hexane extract in Wistar albino rats. International Journal of Basic & Clinical Pharmacology, 6(3), 577–580. https://doi.org/10.18203/2319-2003.ijbcp20170816

Issue

Section

Original Research Articles